Sex: M
Vaccine: COVID19
Symptoms: Eczema, Eczema nummular, Histology, Hypersensitivity, Investigation
Clinical narrative: COVID-19, coronavirus disease 19; COVID-19, coronavirus disease 19; cutaneous eruptions after receiving the COVID vaccine in which the clinical diagnosis was one of a vaccine triggered hypersensitivity reaction; eczematous reaction/features of eczematous dermatitis/eczematous dermatitis characterized by acanthosis, intercellular edema, and exocytosis of lymphocytes and monocytes into the epidermis; the eruption progressed such that nummular plaques involved 10 percent of the body/nummular plaques involved 20 percent of the body; subtle cell-poor-interface dermatitis; A lymphocytic purpuric vascular reaction is also noted; mild psoriasiform epidermal hyperplasia; Overlying areas of lenticular-shaped parakeratosis; This is a literature report for the following literature source(s):   A 64-year-old male patient received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID-19, coronavirus disease 19"; HYPERSENSITIVITY (non-serious), outcome "recovered", described as "cutaneous eruptions after receiving the COVID vaccine in which the clinical diagnosis was one of a vaccine triggered hypersensitivity reaction"; ECZEMA (non-serious), outcome "recovered", described as "eczematous reaction/features of eczematous dermatitis/eczematous dermatitis characterized by acanthosis, intercellular edema, and exocytosis of lymphocytes and monocytes into the epidermis"; ECZEMA NUMMULAR (non-serious), outcome "recovered", described as "the eruption progressed such that nummular plaques involved 10 percent of the body/nummular plaques involved 20 percent of the body"; DERMATITIS (non-serious), outcome "recovered", described as "subtle cell-poor-interface dermatitis"; VASCULAR PURPURA (non-serious), outcome "recovered", described as "A lymphocytic purpuric vascular reaction is also noted"; DERMATITIS PSORIASIFORM (non-serious), outcome "recovered", described as "mild psoriasiform epidermal hyperplasia"; PARAKERATOSIS (non-serious), outcome "recovered", described as "Overlying areas of lenticular-shaped parakeratosis". The patient underwent the following laboratory tests and procedures: Biopsy skin: an eczematous dermatitis characterized by, notes: acanthosis, intercellular edema, and exocytosis of lymphocytes and monocytes into the epidermis. A subtle cell-poor-interface dermatitis was also observed. A lymphocytic purpuric vascular reaction was also noted (hematoxylin and eosin, 200*). Biopsy site: left upper back; Histology: a mild psoriasiform epidermalhyperplasia, notes: There was spongiosis with lymphocytic exocytosis. Overlying areas of lenticular-shaped parakeratosis were identified; T-cell response: T-cell response with features of, notes: an eczematous dermatitis; Microscopy: unknown results.  Clinical course: Cutaneous eruptions after receiving the COVID vaccine in which the clinical diagnosis was one of a vaccine triggered hypersensitivity reaction. The patient developed an eczematous reaction almost immediately after receiving the first dose of the Pfizer COVID-19 vaccine. The eruption progressed such that nummular plaques involved 10 percent of the body. It was also mentioned that nummular plaques involved 20 percent of the body.; Sender's Comments: As there is limited information in the case provided, the causal association between the reported events with the suspect drug BNT162B2 cannot be excluded. The case will be reassessed once new information is available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.,Linked Report(s) : US-PFIZER INC-202300050046 Same reporter/drug, similar event, different patient;